Review · PMID 41956136
Drug Repurposing in Alzheimer's Disease: Emerging Therapeutic Strategies and Promising Candidates — VialBase Research
Elamipretide identified as drug repurposing candidate for Alzheimer's disease
Last updated · 2026 · More PS et al. · Ageing Research Reviews
Key findings
- Elamipretide identified as drug repurposing candidate for Alzheimer's disease
- Targets mitochondrial dysfunction, a key contributor to AD pathogenesis
- Cardiolipin stabilization may protect neurons from bioenergetic failure
- Part of emerging mitochondria-targeted strategies for neurodegenerative disease
PMID 41956136 — Elamipretide as AD Drug Repurposing Candidate
Compound: SS-31 Citation: More PS et al. Ageing Res Rev. 2026 Apr 7:103113. doi:10.1016/j.arr.2026.103113
Summary
Review of drug repurposing strategies for Alzheimer’s disease, identifying elamipretide (SS-31) among emerging candidates targeting mitochondrial dysfunction.
Relevance to SS-31
Mitochondrial dysfunction is increasingly recognized as an early event in AD pathogenesis, preceding amyloid plaque formation. SS-31’s ability to stabilize cardiolipin and restore ETC function could protect neurons from bioenergetic failure. Positions SS-31 as a potential neuroprotective agent beyond its cardiovascular focus.